Danaher (DHR) reported $5.74 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 1%. EPS of $1.88 for the same period compares to $1.92 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $5.56 billion, representing a surprise of +3.34%. The company delivered an EPS surprise of +16.05%, with the consensus EPS estimate being $1.62.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Danaher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Total sales- Diagnostics: $2.45 billion compared to the $2.34 billion average estimate based on three analysts. The reported number represents a change of -3.1% year over year.
- Total sales- Life Sciences: $1.68 billion versus $1.64 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -3.7% change.
- Total sales- Biotechnology: $1.61 billion compared to the $1.59 billion average estimate based on three analysts. The reported number represents a change of +5.8% year over year.
- Operating profit- Life Sciences: $201 million versus the two-analyst average estimate of $199.97 million.
- Operating profit- Biotechnology: $441 million versus $398 million estimated by two analysts on average.
- Operating profit- Other: -$86 million versus the two-analyst average estimate of -$77.15 million.
- Operating profit- Diagnostics: $718 million versus the two-analyst average estimate of $585.46 million.
View all Key Company Metrics for Danaher here>>>
Shares of Danaher have returned -13.1% over the past month versus the Zacks S&P 500 composite's -8.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Danaher Corporation (DHR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
